Cell Line Development Market Analysis

Cell Line Development Market Analysis

Based on product, the cell line development market is segmented into reagents and media, equipment, and accessories and consumables. The reagents and media segment accounted for around 53% market share in 2021. These reagents and media are used for culturing of cells. They are essential for the successful production of physiologically relevant cell models for biomedical research and bioproduction. The reagents and media contain sera and supplements that support cell survival, proliferation, and biological function.
 

Furthermore, the quality of reagents and media affects the experimental results and the production of biotherapeutics. The segmental growth is driven by increasing product approval and new product launches. For instance, in April 2020, CEVEC Pharmaceuticals GmbH announced the launch of the ELEVECTA platform, that will produce stable cell lines for AAV (Adeno-associated viral) vector for gene therapy. The technology increases the production of viral vectors, used in the production of monoclonal antibodies and recombinant proteins.
 

By source, the cell line development market is fragmented into mammalian and non-mammalian cell lines. Among them, the mammalian segment accounted for over USD 4.1 billion in 2021 owing to the frequent use of human cell lines in the expression systems. The mammalian cells undergo post-translational modifications. These modifications are highly exploited in the biomedical research industry.
 

Furthermore, these mammalian cell lines are also used in the production of monoclonal antibodies. These cell lines can express complex proteins similar to human beings useful in development of biologics and research. These factors demand for cell line development and research. Such advantages of mammalian cell lines will propel the cell line development market growth. Furthermore, enhanced cell engineering, advancements in clone screening techniques and protein expression in mammalian cells will foster the overall market growth.
 

The cell line development market based on cell line is classified into recombinant cell lines, hybridomas, primary cell lines and continuous cell lines. The recombinant segment is expected to garner over 9.5% CAGR through 2028. A cell line comprising recombinant DNA for the expression of recombinant proteins is known as recombinant cell line. These cell lines are used for toxicity studies and in-vitro testing. This further increases the demand for cell line development.
 

Furthermore, they are also used in drug discovery programs for assay development. The proteins expressed by recombinant cells are used for screening of target-based identification of compounds. It helps in proper drug screening and development processes.
 

Additionally, technological advancements in expression vector design along with huge R&D expenditure on development of novel products will further propel the cell line development market growth.
 

Based on application, the cell line development market is divided into bioproduction, drug discovery, toxicity testing, tissue engineering and research. The bioproduction segment accounted for around USD 2.7 billion in 2021. Increasing R&D expenditure to produce antibiotics, vaccines and other biological substances will accelerate the segmental as well as market growth.
 

According to WHO, as of January 2022, in total 9 different vaccines have been produced against coronavirus. This rise in production will flourish the market growth. Thus, factors such as increased awareness about vaccination, and production of antibiotics to combat various diseases demand for cell line development.
 

North America cell line development business captured over 34% market share in 2021 and is expected to grow significantly during the forecast years. High regional growth is owing to increased R&D expenditure due to technological developments. These advances are followed by new drug discoveries triggering the adoption of different but unique procedures for bioproduction that will drive the market growth.
 

According to Congressional Research Service, the U.S. R&D expenditure was USD 656 billion. Out of this, 423 billion were spent on various development processes. Such high R&D expenditure along with continuous technological advancements is expected to propel the cell line development market in the forthcoming years.  Moreover, modernizing the cell line development industry for tissue engineering, drug development, studying gene expression, production of bio-therapeutics will further upsurge the cell line development growth.